Waning Immunity & Boosters
How vaccine protection changes over time and what the evidence shows about booster doses
Immunity from vaccination isn't always permanent. For some vaccines, protection lasts a lifetime. For others, it fades over months or years, requiring booster doses to maintain adequate protection.
Understanding waning immunity is essential for public health planning and personal health decisions. It's also a source of confusion — headlines about "waning immunity" can sound alarming, even when protection against severe disease remains strong.
This page explains the science behind immunity waning, which vaccines require boosters, and what the evidence actually shows about declining protection.
How and Why Immunity Wanes
Antibody Levels (Wane Faster)
Antibodies in the blood gradually decline after vaccination or infection. This is measured by antibody titers (concentrations). After months or years, antibody levels may fall below the threshold needed to prevent infection entirely.
Cellular Memory (Wanes Slower)
Memory B cells and T cells can persist for decades, providing longer-term protection. These cells can rapidly produce antibodies and mount cellular responses upon re-exposure to the pathogen.
Key distinction: waning antibody levels do not necessarily mean loss of protection against severe disease. Memory cells can mount a rapid response even if antibodies have declined, often preventing hospitalization and death even if mild infection occurs.
Duration of Protection by Vaccine Type
Long-Lasting (Lifetime or Decades)
- MMR (measles, mumps, rubella) — typically lifelong
- Yellow fever — single dose, decades of protection
- Hepatitis B — long-lasting in most individuals
Medium Duration (Several Years)
- Tdap (tetanus, diphtheria, pertussis) — boosters recommended every 10 years for tetanus component
- Hepatitis A — long-lasting but booster may extend protection further
Shorter Duration (Months to 1-2 Years)
- Seasonal influenza — annual reformulation and vaccination recommended due to antigenic drift
- COVID-19 mRNA vaccines — significant waning of infection protection within months; severe disease protection more durable
Note: Duration data comes from post-licensure surveillance and ongoing studies. Estimates may be updated as more data becomes available.
What Waning Actually Means
A critical distinction that is frequently lost in media coverage:
Infection Protection Wanes Faster
Vaccine-induced protection against mild or symptomatic infection typically declines faster than protection against severe disease. This is because preventing infection entirely requires high circulating antibody levels, while preventing severe disease relies more on memory cell responses.
Severe Disease Protection is More Durable
Protection against hospitalization, ICU admission, and death tends to persist longer than protection against any infection. Memory B and T cells can mount rapid responses that limit disease severity even when antibody levels have declined.
When Are Boosters Recommended?
Booster recommendations are made by ACIP (Advisory Committee on Immunization Practices) based on evidence of waning immunity combined with continued risk of exposure. Factors considered include:
- Rate of antibody decline in vaccinated populations
- Observed breakthrough infection rates over time
- Severity of breakthrough infections vs. unvaccinated
- Population-level risk — who is most vulnerable
- Pathogen evolution — new variants may require updated formulations
Not all vaccines require boosters. The recommendation depends on the specific vaccine, pathogen, and population risk profile.
Limitations and Ongoing Research
- Correlates of protection — the exact antibody or T cell levels needed to prevent disease are not fully established for all vaccines
- Individual variation — waning rates differ between people based on age, immune status, and genetics
- Long-term data is limited for newer vaccines — COVID-19 mRNA vaccines are still being studied for long-term durability
- Booster timing optimization — research continues on optimal intervals for maximum benefit
Sources & Citations
Amanna IJ, Slifka MK. "Mechanisms that determine plasma cell lifespan and the duration of humoral immunity." Immunological Reviews. 2010;236(1):125-138. https://doi.org/10.1111/j.1600-065X.2010.00912.x
Crotty S. "Hybrid immunity." Science. 2021;372(6549):1392-1393. https://doi.org/10.1126/science.abj2258
CDC. "Stay Up to Date with COVID-19 Vaccines." Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html
Patel MM, et al. "Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19." New England Journal of Medicine. 2022;386:1615-1616. https://doi.org/10.1056/NEJMc2200933
WHO. "Immunological Basis for Immunization Series." World Health Organization. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-immunological-basis-for-immunization-series